ScoreWhy is Hubei Goto Biopharm Co., Ltd. ?
1
Poor Management Efficiency with a low ROCE of 3.68%
- The company has been able to generate a Return on Capital Employed (avg) of 3.68% signifying low profitability per unit of total capital (equity and debt)
2
High Debt Company with a Debt to Equity ratio (avg) at times
- Poor long term growth as Net Sales has grown by an annual rate of 2.68% and Operating profit at -187.76% over the last 5 years
- High Debt Company with a Debt to Equity ratio (avg) at times
- The company has been able to generate a Return on Equity (avg) of 4.62% signifying low profitability per unit of shareholders funds
3
Poor long term growth as Net Sales has grown by an annual rate of 2.68% and Operating profit at -187.76% over the last 5 years
4
The company has declared negative results for the last 13 consecutive quarters
- INTEREST(HY) At CNY 23.82 MM has Grown at 127.15%
- OPERATING CASH FLOW(Y) Lowest at CNY -120.02 MM
- ROCE(HY) Lowest at -5.07%
5
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 24.03%, its profits have fallen by -1667.7%
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Hubei Goto Biopharm Co., Ltd. for you?
High Risk, Medium Return
Absolute
Risk Adjusted
Volatility
Hubei Goto Biopharm Co., Ltd.
24.03%
0.48
44.93%
China Shanghai Composite
16.01%
1.07
14.97%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
2.68%
EBIT Growth (5y)
-187.76%
EBIT to Interest (avg)
3.84
Debt to EBITDA (avg)
38.72
Net Debt to Equity (avg)
1.24
Sales to Capital Employed (avg)
0.28
Tax Ratio
31.99%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
3.68%
ROE (avg)
4.62%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
2.71
EV to EBIT
-112.66
EV to EBITDA
69.24
EV to Capital Employed
1.74
EV to Sales
6.07
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-1.54%
ROE (Latest)
-4.34%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bullish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend7What is working for the Company
NET SALES(HY)
At CNY 315.86 MM has Grown at 30.08%
RAW MATERIAL COST(Y)
Fallen by -151.14% (YoY
INVENTORY TURNOVER RATIO(HY)
Highest at 1.19 times
DEBTORS TURNOVER RATIO(HY)
Highest at 3.04 times
-33What is not working for the Company
INTEREST(HY)
At CNY 23.82 MM has Grown at 127.15%
OPERATING CASH FLOW(Y)
Lowest at CNY -120.02 MM
ROCE(HY)
Lowest at -5.07%
DEBT-EQUITY RATIO
(HY)
Highest at 138.76 %
OPERATING PROFIT(Q)
Lowest at CNY -24.02 MM
OPERATING PROFIT MARGIN(Q)
Lowest at -15.73 %
PRE-TAX PROFIT(Q)
Lowest at CNY -30.52 MM
NET PROFIT(Q)
Lowest at CNY -21.28 MM
EPS(Q)
Lowest at CNY -0.18
Here's what is working for Hubei Goto Biopharm Co., Ltd.
Net Sales
At CNY 315.86 MM has Grown at 30.08%
Year on Year (YoY)MOJO Watch
Near term sales trend is positive
Net Sales (CNY MM)
Inventory Turnover Ratio
Highest at 1.19 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its inventory faster
Inventory Turnover Ratio
Debtors Turnover Ratio
Highest at 3.04 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Raw Material Cost
Fallen by -151.14% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Hubei Goto Biopharm Co., Ltd.
Interest
At CNY 23.82 MM has Grown at 127.15%
over previous Semi-Annual periodMOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (CNY MM)
Pre-Tax Profit
At CNY -30.52 MM has Fallen at -114.21%
over average net sales of the previous four periods of CNY -14.25 MMMOJO Watch
Near term Pre-Tax Profit trend is very negative
Pre-Tax Profit (CNY MM)
Net Profit
At CNY -21.28 MM has Fallen at -153.17%
over average net sales of the previous four periods of CNY -8.41 MMMOJO Watch
Near term Net Profit trend is very negative
Net Profit (CNY MM)
Debt-Equity Ratio
Highest at 138.76 % and Grown
In each half year in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
Operating Cash Flow
Lowest at CNY -120.02 MM
in the last three yearsMOJO Watch
The company's cash revenues from business operations are falling
Operating Cash Flows (CNY MM)
Operating Profit
Lowest at CNY -24.02 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is negative
Operating Profit (CNY MM)
Operating Profit Margin
Lowest at -15.73 %
in the last five periodsMOJO Watch
Company's profit margin has deteriorated
Operating Profit to Sales
Pre-Tax Profit
Lowest at CNY -30.52 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is negative
Pre-Tax Profit (CNY MM)
Net Profit
Lowest at CNY -21.28 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is negative
Net Profit (CNY MM)
EPS
Lowest at CNY -0.18
in the last five periodsMOJO Watch
Declining profitability; company has created lower earnings for shareholders
EPS (CNY)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
